Loading…

68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranost...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2024-02, Vol.85 (1), p.e22136-e22136
Main Authors: Karpuz, Merve, Ozgenc, Emre, Oner, Ezgi, Atlihan-Gundogdu, Evren, Burak, Zeynep
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c903-d523e01598bafed44d9e9dbe1fb2c5d1f310ea1246ccea8a849922edb08298f3
container_end_page e22136
container_issue 1
container_start_page e22136
container_title Drug development research
container_volume 85
creator Karpuz, Merve
Ozgenc, Emre
Oner, Ezgi
Atlihan-Gundogdu, Evren
Burak, Zeynep
description Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranostic agents for breast cancer. After the characterization studies in which all liposomes exhibited proper profile owing to their particle size between 133 and 250 nm, polydispersity index values lower than 0.4, neutral and cationic zeta potential values, and high drug encapsulation efficiency, controlled drug release behaviors with zero-order kinetic were obtained. The higher than 90% radiolabeling efficiency values were obtained thanks to the determination of optimum radiolabeling condition (80°C temperature, 5 mCi radioactivity, and 10 min incubation period). According to the resazurin assay evaluating the cytotoxic profile of liposomes on MCF7 cells, neutral empty liposome was found as biocompatible, while both cationic liposomes (empty and drug-loaded ones) exhibited high nonspecific cytotoxicity at even low drug concentration due to the existence of stearyl amine in the formulations. However, dose-dependent cytotoxic effect and the highest cellular binding capacity were obtained by imatinib loaded neutral liposomes. In conclusion, Ga-radiolabeled, imatinib-loaded, neutral, nanosized liposome formulation is the most promising one as a theranostic agent among all formulations.
doi_str_mv 10.1002/ddr.22136
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2894361723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2894361723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c903-d523e01598bafed44d9e9dbe1fb2c5d1f310ea1246ccea8a849922edb08298f3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWw4AeQlyA1xY80tdmhihakSixgH03siWqUxMVOkMon8NWkD1iNdO-ZuziEXHM24YyJe2vDRAgusxMy5EyrRAitT8mQiZlIUqn5gFzE-MEY56lS52QgFWM6FXJIfjJFl5BUUGCFdkxdDa1rXEGxMbCJXQXtLm7XGKDxsXWGVm7jo68xPtCFD_UOcb4ZU7OGAKbF4L6PCTSWuoZ-uTZ4il9QdfuC-rKv-iloDAba_7ge2V6SsxKqiFfHOyJvi6f3-XOyel2-zB9XidFMJnYqJDI-1aqAEm2aWo3aFsjLQpip5aXkDIGLNDMGQYFKtRYCbcGU0KqUI3J7WN0E_9lhbPPaRYNVBQ36LuZC6VRmfCZkj94dUBN8jAHLfBN6P2Gbc5bvxOe9-HwvvmdvjrNdUaP9J_9My19u8IEx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2894361723</pqid></control><display><type>article</type><title>68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Karpuz, Merve ; Ozgenc, Emre ; Oner, Ezgi ; Atlihan-Gundogdu, Evren ; Burak, Zeynep</creator><creatorcontrib>Karpuz, Merve ; Ozgenc, Emre ; Oner, Ezgi ; Atlihan-Gundogdu, Evren ; Burak, Zeynep</creatorcontrib><description>Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranostic agents for breast cancer. After the characterization studies in which all liposomes exhibited proper profile owing to their particle size between 133 and 250 nm, polydispersity index values lower than 0.4, neutral and cationic zeta potential values, and high drug encapsulation efficiency, controlled drug release behaviors with zero-order kinetic were obtained. The higher than 90% radiolabeling efficiency values were obtained thanks to the determination of optimum radiolabeling condition (80°C temperature, 5 mCi radioactivity, and 10 min incubation period). According to the resazurin assay evaluating the cytotoxic profile of liposomes on MCF7 cells, neutral empty liposome was found as biocompatible, while both cationic liposomes (empty and drug-loaded ones) exhibited high nonspecific cytotoxicity at even low drug concentration due to the existence of stearyl amine in the formulations. However, dose-dependent cytotoxic effect and the highest cellular binding capacity were obtained by imatinib loaded neutral liposomes. In conclusion, Ga-radiolabeled, imatinib-loaded, neutral, nanosized liposome formulation is the most promising one as a theranostic agent among all formulations.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.22136</identifier><identifier>PMID: 38009423</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - chemistry ; Breast Neoplasms - drug therapy ; Female ; Humans ; Imatinib Mesylate - pharmacology ; Liposomes - chemistry ; Liposomes - therapeutic use ; Particle Size ; Precision Medicine</subject><ispartof>Drug development research, 2024-02, Vol.85 (1), p.e22136-e22136</ispartof><rights>2023 The Authors. Drug Development Research published by Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c903-d523e01598bafed44d9e9dbe1fb2c5d1f310ea1246ccea8a849922edb08298f3</cites><orcidid>0000-0001-6681-2448</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38009423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karpuz, Merve</creatorcontrib><creatorcontrib>Ozgenc, Emre</creatorcontrib><creatorcontrib>Oner, Ezgi</creatorcontrib><creatorcontrib>Atlihan-Gundogdu, Evren</creatorcontrib><creatorcontrib>Burak, Zeynep</creatorcontrib><title>68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity</title><title>Drug development research</title><addtitle>Drug Dev Res</addtitle><description>Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranostic agents for breast cancer. After the characterization studies in which all liposomes exhibited proper profile owing to their particle size between 133 and 250 nm, polydispersity index values lower than 0.4, neutral and cationic zeta potential values, and high drug encapsulation efficiency, controlled drug release behaviors with zero-order kinetic were obtained. The higher than 90% radiolabeling efficiency values were obtained thanks to the determination of optimum radiolabeling condition (80°C temperature, 5 mCi radioactivity, and 10 min incubation period). According to the resazurin assay evaluating the cytotoxic profile of liposomes on MCF7 cells, neutral empty liposome was found as biocompatible, while both cationic liposomes (empty and drug-loaded ones) exhibited high nonspecific cytotoxicity at even low drug concentration due to the existence of stearyl amine in the formulations. However, dose-dependent cytotoxic effect and the highest cellular binding capacity were obtained by imatinib loaded neutral liposomes. In conclusion, Ga-radiolabeled, imatinib-loaded, neutral, nanosized liposome formulation is the most promising one as a theranostic agent among all formulations.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Imatinib Mesylate - pharmacology</subject><subject>Liposomes - chemistry</subject><subject>Liposomes - therapeutic use</subject><subject>Particle Size</subject><subject>Precision Medicine</subject><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqWw4AeQlyA1xY80tdmhihakSixgH03siWqUxMVOkMon8NWkD1iNdO-ZuziEXHM24YyJe2vDRAgusxMy5EyrRAitT8mQiZlIUqn5gFzE-MEY56lS52QgFWM6FXJIfjJFl5BUUGCFdkxdDa1rXEGxMbCJXQXtLm7XGKDxsXWGVm7jo68xPtCFD_UOcb4ZU7OGAKbF4L6PCTSWuoZ-uTZ4il9QdfuC-rKv-iloDAba_7ge2V6SsxKqiFfHOyJvi6f3-XOyel2-zB9XidFMJnYqJDI-1aqAEm2aWo3aFsjLQpip5aXkDIGLNDMGQYFKtRYCbcGU0KqUI3J7WN0E_9lhbPPaRYNVBQ36LuZC6VRmfCZkj94dUBN8jAHLfBN6P2Gbc5bvxOe9-HwvvmdvjrNdUaP9J_9My19u8IEx</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Karpuz, Merve</creator><creator>Ozgenc, Emre</creator><creator>Oner, Ezgi</creator><creator>Atlihan-Gundogdu, Evren</creator><creator>Burak, Zeynep</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6681-2448</orcidid></search><sort><creationdate>202402</creationdate><title>68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity</title><author>Karpuz, Merve ; Ozgenc, Emre ; Oner, Ezgi ; Atlihan-Gundogdu, Evren ; Burak, Zeynep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c903-d523e01598bafed44d9e9dbe1fb2c5d1f310ea1246ccea8a849922edb08298f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Imatinib Mesylate - pharmacology</topic><topic>Liposomes - chemistry</topic><topic>Liposomes - therapeutic use</topic><topic>Particle Size</topic><topic>Precision Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karpuz, Merve</creatorcontrib><creatorcontrib>Ozgenc, Emre</creatorcontrib><creatorcontrib>Oner, Ezgi</creatorcontrib><creatorcontrib>Atlihan-Gundogdu, Evren</creatorcontrib><creatorcontrib>Burak, Zeynep</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karpuz, Merve</au><au>Ozgenc, Emre</au><au>Oner, Ezgi</au><au>Atlihan-Gundogdu, Evren</au><au>Burak, Zeynep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity</atitle><jtitle>Drug development research</jtitle><addtitle>Drug Dev Res</addtitle><date>2024-02</date><risdate>2024</risdate><volume>85</volume><issue>1</issue><spage>e22136</spage><epage>e22136</epage><pages>e22136-e22136</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><abstract>Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranostic agents for breast cancer. After the characterization studies in which all liposomes exhibited proper profile owing to their particle size between 133 and 250 nm, polydispersity index values lower than 0.4, neutral and cationic zeta potential values, and high drug encapsulation efficiency, controlled drug release behaviors with zero-order kinetic were obtained. The higher than 90% radiolabeling efficiency values were obtained thanks to the determination of optimum radiolabeling condition (80°C temperature, 5 mCi radioactivity, and 10 min incubation period). According to the resazurin assay evaluating the cytotoxic profile of liposomes on MCF7 cells, neutral empty liposome was found as biocompatible, while both cationic liposomes (empty and drug-loaded ones) exhibited high nonspecific cytotoxicity at even low drug concentration due to the existence of stearyl amine in the formulations. However, dose-dependent cytotoxic effect and the highest cellular binding capacity were obtained by imatinib loaded neutral liposomes. In conclusion, Ga-radiolabeled, imatinib-loaded, neutral, nanosized liposome formulation is the most promising one as a theranostic agent among all formulations.</abstract><cop>United States</cop><pmid>38009423</pmid><doi>10.1002/ddr.22136</doi><orcidid>https://orcid.org/0000-0001-6681-2448</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0272-4391
ispartof Drug development research, 2024-02, Vol.85 (1), p.e22136-e22136
issn 0272-4391
1098-2299
language eng
recordid cdi_proquest_miscellaneous_2894361723
source Wiley-Blackwell Read & Publish Collection
subjects Antineoplastic Agents - chemistry
Breast Neoplasms - drug therapy
Female
Humans
Imatinib Mesylate - pharmacology
Liposomes - chemistry
Liposomes - therapeutic use
Particle Size
Precision Medicine
title 68 Ga-labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A27%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=68%20Ga-labeled,%20imatinib%20encapsulated,%20theranostic%20liposomes:%20Formulation,%20characterization,%20and%20in%20vitro%20evaluation%20of%20anticancer%20activity&rft.jtitle=Drug%20development%20research&rft.au=Karpuz,%20Merve&rft.date=2024-02&rft.volume=85&rft.issue=1&rft.spage=e22136&rft.epage=e22136&rft.pages=e22136-e22136&rft.issn=0272-4391&rft.eissn=1098-2299&rft_id=info:doi/10.1002/ddr.22136&rft_dat=%3Cproquest_cross%3E2894361723%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c903-d523e01598bafed44d9e9dbe1fb2c5d1f310ea1246ccea8a849922edb08298f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2894361723&rft_id=info:pmid/38009423&rfr_iscdi=true